RG6468 / Roche - LARVOL DELTA

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=65 | Active, not recruiting | Sponsor: Genentech, Inc. | N=250 ➔ 65 | Trial completion date: Dec 2027 ➔ Mar 2027 | Trial primary completion date: Dec 2027 ➔ Mar 2027 | Recruiting ➔ Active, not recruiting

Enrollment change • Enrollment closed • First-in-human • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Further back in Roche’s pipeline, the company discontinued a clutch of phase 1-stage drugs (FierceBiotech) - "Aside from the TCE, these included mosperafenib, a BRAF inhibitor that was being evaluated for solid tumors....Mosperafenib was joined on the discard pile by another solid tumor candidate in the form of RG6468, which was being assessed in combination with Tecentriq. Roche didn’t confirm RG6468’s mode of action, but did tell Fierce that the company had decided to halt the program after reviewing the phase 1 data."

Discontinued • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=250 | Recruiting | Sponsor: Genentech, Inc. | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=250 | Recruiting | Sponsor: Genentech, Inc. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=250 | Not yet recruiting | Sponsor: Genentech, Inc.

Combination therapy • Metastases • New P1 trial • Oncology • Solid Tumor